Pfizer Loses U.K. Patent Appeal Over $4.8 Billion Lyrica Drug
This article is for subscribers only.
Pfizer Inc. lost an appeal in a U.K. patent dispute over Lyrica, one of the company’s top-selling drugs.
Three London judges upheld a 2015 ruling that Allergan Plc’s Actavis unit didn’t infringe Pfizer patents with its version of the drug pregabalin. The disputed patent covers the use of pregabalin for the treatment of pain. Teva bought the business this year.